JACKSON, Mississippi — The University of Mississippi Medical Center is offering faster, more precise radiotherapy after installing two Varian systems, Edge and Ethos, at its radiation oncology center, part of the UMMC Cancer Center and Research Institute.
The center has the only Ethos system in Mississippi, which uses artificial intelligence for adaptive radiation therapy to allow real‑time adjustments, officials said. Patrick McCarthy of Jackson, one of the first patients in the state to receive treatment with Ethos, is undergoing radiation and chemotherapy for squamous cell carcinoma after a 13‑day hospital stay.
“It’s been one of the best decisions I’ve ever made. The care I’ve had has been incredible,” McCarthy said.
The Edge model provides sub‑millimeter accuracy and, when paired with an onboard surface‑guided imaging system, delivers stereotactic radiosurgery — a noninvasive, highly precise treatment that targets tumors with three‑dimensional imaging and high‑dose radiation, Dr. Neil Duggar, associate professor of radiation oncology, said. On‑table imaging can be done in six seconds, and treatments on the new systems are shorter, he said.
“If a tumor shrinks or moves, adjustments are made to reduce radiation exposure for healthy tissue and minimize side effects,” Duggar said. Dr. Rojymon Jacob, chair of the department of radiation oncology, said combining real‑time imaging, adaptive planning and sub‑millimeter accuracy gives patients safer treatments and more options.
The new equipment occupies a renovated space at University Hospital while the center plans a new five‑story cancer facility that is on the drawing board. Radiation oncology clinic appointments are now at the CCRI location in the UMMC Medical Pavilion. The building is funded in part by It’s About Time: The Campaign for the UMMC Cancer Center and Research Institute, a $125 million philanthropic drive, and will combine advanced care and research, officials said.
“Mississippians deserve the most advanced cancer care available right here at home,” said Dr. Rod Rocconi, Ergon Chair for Cancer Research and CCRI director. This is a developing story and will be updated as more details emerge.
